薄芝糖肽与舒血宁注射液联合应用治疗椎基底动脉供血不足的临床研究  

Clinical Study on Treating Vertebrobasilar Insufficiency by Bozhi Glycopeptide and Shuxuening Injection

作　　者：郑仕成[1] 郑世文[2] 

机构地区：[1]济南市第五人民医院药剂科,山东济南250022 [2]济南市第五人民医院内四科,山东济南250022

出　　处：《中国医药指南》2016年第18期15-16,共2页Guide of China Medicine

摘　　要：目的探讨薄芝糖肽与舒血宁注射液联合应用治疗椎基底动脉供血不足的疗效、作用机制。方法随机将60例椎基底动脉供血不足患者分为两组,治疗组与对照组各为30例。治疗组给予薄芝糖肽与舒血宁注射液联合治疗,对照组单用舒血宁注射液治疗。10 d为1个疗程。治疗前后分别测定血液流变学、血流动力学参数及肝肾功能指标,同时观察临床疗效。结果治疗组在改善血液流变学、MCA血流动力学参数方面优于对照组(P<0.05),两组的有效率分别为93.3%、86.7%(P<0.05)。结论薄芝糖肽与舒血宁注射液联合应用治疗椎基底动脉供血不足安全且效果好。Objective To explore the clinical effect and mechanism of treating Vertebrobasilar insufficiency（VBI） by Bozhi Glycopeptide and Shuxuening injection. Methods 60 VBI patients, randomly divided into treatment group and contrast group, every group has 30 cases. The treatment group is treated by Bozhi Glycopeptide and Shuxuening injection. The contrast group is treated without Bozhi Glycopeptide. A course of treatment is 10 days. Blood rheology and MCA blood flow dynamics, liver and kidney function indexes were measured before and after treatment. Observe the clinical effect at the same time. Results In the aspects of improving blood viscosity and MCA blood dynamical parameters, the treatment group is obviously superior to the contrast group. The total effective rate in the treatment group reached 93.3%, while in the contrast group, the total effective rate is only 86.7%. There is a remarkable difference between the two groups（P〈0.05）. Conclusion Bozhi Glycopeptide combined with Shuxuening injection in treatment of VBI is safe and effective.

关 键 词：椎基底动脉供血不足 薄芝糖肽 舒血宁 

分 类 号：R743.3[医药卫生—神经病学与精神病学]